Oxurion NV (OXUR.BR)

EUR 0.08

(-2.44%)

Long Term Debt Summary of Oxurion NV

  • Oxurion NV's latest annual long term debt in 2023 was 117 Thousand EUR , down -96.38% from previous year.
  • Oxurion NV's latest quarterly long term debt in 2024 Q2 was - EUR , down 0.0% from previous quarter.
  • Oxurion NV reported annual long term debt of 3.23 Million EUR in 2022, down -61.64% from previous year.
  • Oxurion NV reported annual long term debt of 8.43 Million EUR in 2021, up 1786.58% from previous year.
  • Oxurion NV reported quarterly long term debt of 117 Thousand EUR for 2023 FY, down -96.38% from previous quarter.
  • Oxurion NV reported quarterly long term debt of 117 Thousand EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Oxurion NV (2023 - 2006)

Historical Annual Long Term Debt of Oxurion NV (2023 - 2006)

Year Long Term Debt Long Term Debt Growth
2023 117 Thousand EUR -96.38%
2022 3.23 Million EUR -61.64%
2021 8.43 Million EUR 1786.58%
2020 447 Thousand EUR -66.52%
2019 1.33 Million EUR 0.0%
2018 - EUR 0.0%
2017 - EUR 0.0%
2016 - EUR 0.0%
2015 - EUR 0.0%
2014 - EUR 0.0%
2013 - EUR 0.0%
2012 - EUR 0.0%
2011 - EUR 0.0%
2010 - EUR 0.0%
2009 - EUR 0.0%
2008 - EUR 0.0%
2007 - EUR 0.0%
2006 - EUR 0.0%

Peer Long Term Debt Comparison of Oxurion NV

Name Long Term Debt Long Term Debt Difference
Nicox S.A. 25.15 Million EUR 99.535%
European Medical Solutions 12.71 Million EUR 99.08%
FERMENTALG 14.33 Million EUR 99.184%
argenx SE 15.35 Million EUR 99.238%
BioSenic S.A. 15.57 Million EUR 99.249%
Celyad Oncology SA 902 Thousand EUR 87.029%
Hyloris Pharmaceuticals SA 344 Thousand EUR 65.988%
Onward Medical N.V. 16.3 Million EUR 99.282%
PHAXIAM Therapeutics S.A. 7.03 Million EUR 98.336%
Financière de Tubize SA - EUR -Infinity%
UCB SA 2.87 Billion EUR 99.996%